不适合标准免疫化疗的老年及不适合强化治疗套细胞淋巴瘤患者的治疗模式与结局:英国和爱尔兰分析
该多中心回顾性分析纳入英国和爱尔兰19个中心的95例不适合全剂量R-CHOP或R-苯达莫司汀的套细胞淋巴瘤患者,评估减量免疫化疗的结局。较高治疗强度与更优PFS独立相关,母细胞形态与更差PFS和OS相关。
要点
- 较高强度方案(减量R-CHOP或减量R-苯达莫司汀)较R-CVP或R-氯苯丁酸氮芥有更优PFS。
- 母细胞形态是PFS和OS的不良预后因素,ECOG PS和24个月内进展也影响OS。
核心结论
- 在不适合全剂量免疫化疗的老年套细胞淋巴瘤患者中,一线减量免疫化疗的生存结局不令人满意。
- 需要在该特定临床人群中开展新型药物(如BTK抑制剂和BCL-2抑制剂)的临床试验。
研究设计与样本
- 多中心回顾性分析,纳入英国和爱尔兰19个中心的95例套细胞淋巴瘤患者。
- 患者被认为不适合全剂量利妥昔单抗-苯达莫司汀或R-CHOP方案。
- 治疗方案包括R-CVP(n=19)、减量R-CHOP(n=22)、减量利妥昔单抗-苯达莫司汀(n=24)和利妥昔单抗-氯苯丁酸氮芥(n=30)。
- 主要终点为无进展生存期(PFS),次要终点包括总缓解率、总生存期(OS)和毒性。
主要发现
- 中位年龄79岁(范围58-89岁),50%患者年龄≥80岁;中位累积疾病评定量表-老年版评分为6分(范围0-24)。
临床怎么用
- 对于不适合全剂量免疫化疗的老年套细胞淋巴瘤患者,可考虑较高强度的减量方案(如减量R-CHOP或减量R-苯达莫司汀)以改善PFS。
- 母细胞形态、ECOG PS较差和24个月内进展提示预后不良,应加强监测和个体化治疗决策。
- 鼓励此类患者参加评估BTK抑制剂和BCL-2抑制剂等新型药物的临床试验。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 样本量较小(95例),各治疗方案亚组例数有限。
- 未报告毒性结果的具体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients with MCL across 19 centres in the UK and Ireland considered unfit for full-dose rituximab-bendamustine or rituximab-cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP). Regimens examined were rituximab-cyclophosphamide, vincristine, prednisolone (R-CVP) (n = 19), dose-attenuated R-CHOP (n = 22), dose attenuated rituximab-bendamustine (n = 24) and rituximab-chlorambucil (n = 30). The primary outcome was progression-free survival (PFS). The secondary outcomes included overall response, overall survival (OS) and toxicity. The median (range) age was 79 (58-89) years and 50% were aged ≥80 years. The median (range) Cumulative Illness Rating Scale-Geriatric score was 6 (0-24). The median PFS for all patients was 15 months [95% confidence interval (CI) 8·7-21·2) and median OS was 31·4 months (95% CI 19·7-43·2). By multivariable analysis (MVA), the only clinical factor associated with an inferior PFS was blastoid morphology [hazard ratio (HR) 2·90, P = 0·01). Notably, higher treatment intensity (R-CHOP/R-bendamustine composite) provided an independently superior PFS compared with R-CVP/R-chlorambucil (MVA HR 0·49, P = 0·02). Factors associated with inferior OS by MVA were Eastern Cooperative Oncology Group Performance Status (HR 2·14, P = 0·04), blastoid morphology (HR 4·08, P = 0·001) and progression of disease at <24 months status (HR 5·68, P < 0·001). Overall, survival after front-line dose-attenuated immunochemotherapy is unsatisfactory. Clinical trials investigating novel agents such as Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors in this specific clinical setting are warranted.
引用
- Rampotas A, Wilson MR, Lomas O, et al. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. Br J Haematol. 2021. PMID: 33959947. doi:10.1111/bjh.17513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。